HRT Financial LP Sells Shares of CMND $CMND

Key Points

  • HRT Financial LP sold 225,191 shares of Clearmind Medicine Inc. ($CMND) worth $27,022.92.
  • $CMND last traded around $3.34.

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

HRT Financial LP, insider at Clearmind Medicine Inc. ($CMND), sold 225,191 shares at an average price of $0.12, for a total transaction of $27,022.92. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.

Clearmind Medicine Inc. Stock Up 89.2%

Shares of Clearmind Medicine Inc. ($CMND) traded around $3.34 on Saturday, up 89.2% for the day.

Last price$3.34
Market cap$2.88M
Beta-1.18
52-week low$1.43
52-week high$524
50-day MA$1.92
200-day MA$15.99
Current ratio4.79
Quick ratio4.73
Debt-to-equity0.01

Clearmind Medicine Inc. Earnings

EPS (ttm)-$175.92
Revenue (ttm)
Net margin0%
Return on equity-114.61%

About Clearmind Medicine Inc.

Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, the company has a strategic collaboration with SciSparc Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem, Polyrizon Ltd., and NeuroThera Labs Inc. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

ExchangeNasdaqCM
SectorHealthcare
IndustryBiotechnology
HeadquartersVancouver, BC
CEODr. Adi Zuloff-Shani Ph.D.

Get Clearmind Medicine Inc. alerts

New 13F filings, insider trades, and analyst moves on $CMND, sent to your inbox. Free, and you can unsubscribe anytime.

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.